Company / Working Capital
Stoke Therapeutics, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$247.8M
FY2025
5-year range
$184.5M / $247.8M
FY2021-FY2025
Trend
+28.6%
vs FY2024
Sector context
#159 of 213
Health Care
What the data says
Stoke Therapeutics, Inc.'s working capital of $248M is lower than 75% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 8 years, ranging from $104M in FY2018 to $283M in FY2020.
Based on SEC 10-K filings.
$248M in FY2025 with a 5-year CAGR of -2.6%.
Improved from $185M to $248M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +5.2%
- 5-Year CAGR
- -2.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 213This company $247.8M Sector average $934.6M
▼
-73.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.6%, indicating a declining trend.
- In FY2025, working capital increased 28.6% year-over-year.
- Ranks #159 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $247.8M | +28.6% |
| FY2024 | $192.7M | +4.4% |
| FY2023 | $184.5M | -13.2% |
| FY2022 | $212.7M | +0.3% |
| FY2021 | $212.1M | -24.9% |
| FY2020 | $282.5M | +27.3% |
| FY2019 | $221.9M | +114.1% |
| FY2018 | $103.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026